

# Lisa M. Hess, Ph.D.

## Curriculum Vitae

---

Indiana University/Purdue University-Indianapolis  
IU Department of Public Health  
714 N. Senate Avenue, Suite EF250  
Indianapolis, IN 46202  
(317) 274-3148  
Fax (317) 274-3443  
[lmhess@iupui.edu](mailto:lmhess@iupui.edu)

**Birthplace:** Albany, New York, U.S.A.

### **P R O F E S S I O N A L   E X P E R I E N C E**

- 2008-present**      ***Indiana University***  
Assistant Professor  
Department of Public Health and Department of Obstetrics and Gynecology  
Simon Cancer Center  
IU School of Medicine, Indianapolis IN
- 2003-2008**      ***University of Arizona***  
Scientific Investigator/Science Officer, Cancer Center Division  
Arizona Cancer Center, Tucson AZ
- 2002-2008**      ***University of Arizona***  
Assistant Director, R25T Cancer Prevention Postdoctoral Fellowship Program  
Arizona Cancer Center, Tucson AZ
- 2001-2008**      ***University of Arizona***  
Core Leader, Adherence Core, Skin Cancer Chemoprevention Program Project  
P01 NCI NIH (PI-Alberts)
- 1999-2008**      ***Gynecologic Oncology Group (GOG)***  
Research Administrator, CCOP Program/Cancer Prevention and Control Committee  
Gynecologic Oncology Group
- 2001-2003**      ***University of Arizona***  
Core Leader, Adherence Core, Colon Cancer Prevention Program Project  
P01 NCI NIH (PI-Alberts)
- 1993-2002**      ***University of Arizona***  
Research Specialist, Senior/Principal  
Arizona Cancer Center, Tucson AZ
- 1992-1993**      ***University of Arizona***  
Graduate Research Assistant  
Arizona Cancer Center, Tucson AZ

---

---

**C O N S U L T I N G   E X P E R I E N C E**

- 2001-present**    *Cancer Technologies, Inc.*  
Editor in the development of cancer staging/grading devices; Tim Alberts, MBA, MPH
- 2008**            *Dymaxium, Inc.*  
Development of a technical white paper on the assessment of adherence using administrative databases; Bridget Olson, PharmD, MS
- 2007**            *University of Arkansas*  
Grant review; implementation and development of educational program in family and community medicine; Geoffrey Goldsmith, M.D., M.P.H.
- 2007**            *Health Research Alliance Arizona*, joint venture of the State of Arizona universities, colleges and health care systems and providers  
Grant review/writing and curriculum development related to the statewide K12, T32, Masters and Doctoral degree and certificate programs proposed for the State of Arizona in clinical and translational research; Keith Joiner, M.D. and Peter Lance, M.D.
- 2003-2006**    *Translational Genomics Research Institute (TGen)*  
Grant review and grant writing; implementation of fellowship training program in translational genomics; Jeffrey Trent, Ph.D.
- 2005**            *Arizona State University*  
Grant review, writing and organization/budgets; Joan McGregor, Ph.D.
- 2000-2005**    *Medical Directions, Inc.*  
Development of pharmaceutical training materials (Zometa/Pharmacia)  
Development/maintenance of web site CME programs in Ovarian Oncology; Skip Harris, M.D.
- 2002**            *Triple i Oncology/Medimedia*  
Development of CME related to Hexalen(Altretamine)/MGI Pharma; Cassandra J. Galligher, RN, MSN, CRNP
- 2001**            *IHS Clinical Support Center/COM*  
Development of materials for National Native American Traditional Healers Conference, Scottsdale AZ; Kris Olson, M.D.
- 2000-2002**    *American Society of Preventive Oncology*  
Career development and meeting materials for annual meetings in Bethesda MD; Mary Reid, Ph.D.

## **E D U C A T I O N**

- 2007**                    **Doctor of Philosophy – Pharmaceutical Sciences**  
 University of Arizona, Tucson AZ  
 Major: Pharmaceutical Economics, Policy and Outcomes  
 Minor: Nursing  
 Dissertation: *Pilot Study of Patient and Oncologist Preferences for Chemotherapy Treatment of Advanced Ovarian Cancer*  
 Minor paper: *Pilot study of the emotional well-being of Hispanic women age 40-59 in the Southwest United States*  
 GPA 4.0
- 2005**                    **Master of Science – Pharmaceutical Sciences**  
 University of Arizona, Tucson AZ  
 Thesis: *A meta-analysis of intraperitoneal cisplatin therapy for advanced ovarian cancer*  
 GPA 4.0
- 1999**                    **Master of Arts – Latin American Studies**  
 University of Arizona, Tucson AZ  
 Thesis: *Infant mortality in Brazil during periods of economic instability*  
 GPA 3.8
- 1990**                    **Bachelor of Arts, Magna Cum Laude**  
 Siena College, Loudonville NY  
 Spanish and Psychology  
 GPA 3.9
- 1989**                    **Instituto Hispano-Americano**  
 Sevilla, España (Spain)  
 Intensive Spanish/cultural coursework to complement major undergraduate degree.

## **A C A D E M I C   A W A R D S   A N D   H O N O R S**

- 1992**                    Associated Students of the University of Arizona (ASUA) Merit Graduate Student Scholarship
- 1991**                    University of Arizona Graduate Student Showcase—first place award for presentation of work in housing project Belo Horizonte, Brazil
- 1989**                    Intercollegiate Legislative Assembly – best bill award
- 1986**                    Siena College Scholar Incentive Award
- 1986**                    MaryBeth Weigner Scholarship

## **M E M B E R S H I P S**

American Association of Cancer Research  
 American Public Health Association  
 International Society of Gynecologic Oncology  
 Society of Medical Decision Making  
 American Psychosocial Oncology Society  
 Psi Chi, National Honor Society in Psychology  
 Alpha Mu Gamma, National Honor Society for Outstanding Achievement in Foreign Languages  
 Alpha Kappa Alpha, Highest Honor Society of Siena College

**P U B L I C A T I O N S**

Jacobs, ET, Giuliano, AR, Roe DJ, Guillen-Rodriguez JM, **Hess LM**, Alberts DS. Martinez EM. Intake of Supplemental and Total Fiber and Risk of Colorectal Adenoma Recurrence in the Wheat Bran Fiber Trial. Cancer Epidem Biom Prev 11:906-914, 2002.

Alberts DS, Einspahr J, Earnest DL, Krutzsch M, Lin P, **Hess LM**, Heddens DS, Roe D, Martinez ME, Salen G, Batta AK. Fecal Bile Acid Concentrations in a Subpopulation Within the Wheat Bran Fiber Colon Cancer Prevention Trial, Cancer Epi Biom Prev, 12(3):197-200, 2003.

**Hess LM**, Krutzsch MF, Guillen J, Chow HHS, Einspahr J, Batta AK, Salen G, Reid ME, Earnest DL, Alberts DS. Results of a Phase I Multiple-Dose Clinical Study of Ursodeoxycholic Acid (UDCA). Cancer Epi Biom Prev, 13(5):861-867, 2004.

Alberts DS, Martinez EM, **Hess LM**, Einspahr JG, Green SB, Bhattacharyya AB, Guillen J, Krutzsch M, Batta AK, Salen G, Fales L, Koonce K, Parish D, Clouser M, Roe D, Lance P. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. JNCI. 97(10):846-53, 2005.

Alberts DS, Potter J, Martinez ME, **Hess LM** and Lance P. What Happened to the Coxibs on the Way to the Cardiologist? Cancer Epi Biom Prev, 14(3):555-556, 2005.

**Hess LM**, Saboda K, Malone DC, Salasche S, Warneke J, and Alberts DS. Adherence assessment using medication weight in a phase IIb clinical trial of difluoromethylornithine for the chemoprevention of skin cancer. Cancer Epi Biom Prev, 14(11):2579-83, 2005.

**Hess LM**, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacology, 40(7-8):1280-88, 2006.

Bartels, P, Ranger-Moore, J, Alberts, D, **Hess, L**, Scarpelli, M, and Montironi, R. Carcinogenesis and the hypothesis of phylogenetic reversion. Analytical and Quantitative Cytology and Histology, 28(5):243-52, 2006.

Alberts DS, Bookman MA, Chen T, Curtin J, Eldermire E, **Hess LM**, Liebes L, Markman M, Muggia F, Ozols RF, Young RC, and Trimble E. Proceedings of a GOG Workshop on Intraperitoneal Therapy for Ovarian Cancer. Gyn Onc, 103(3):783-92, 2006.

**Hess LM**, Benham-Hutchins M, Herzog P, Hsu C, Malone DC, Skrepnek GH, Slack M, Alberts DS. A meta-analysis of intraperitoneal versus intravenous cisplatin-based chemotherapy for the front-line treatment of ovarian cancer. Int J Gyn Cancer, 17(3):561-70, 2007.

**Hess LM**, Barakat R, Tian C, Ozols RF, and Alberts DS. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gyn Onc, 107:260-265, 2007.

**Hess LM** and Alberts DS. The Role of Intraperitoneal Therapy in Advanced Ovarian Cancer. Oncology, 21(2):227-231, 2007.

**Hess LM** and Insel KC. A conceptual model of chemotherapy-associated change in cognitive function. Onc Nursing Forum, 34(5):981-994, 2007.

Alberts DS, Einspahr JG, Krouse RS, Prasad A, Ranger-Moore, J, Hamilton P, Ismail A, Lance P, Goldschmit S, **Hess LM**, Yozwiak M, Bartels HG, Bartels PH. Karyometry of the colonic mucosa. Cancer Epi Biom Prev, 16(12):2704-2716, 2007.

**Hess LM**, Benham-Hutchins M, Jeter J, Alberts DS. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med, 121(6):475-483, 2008.

Bartels, PH, Yozwiak M, Bartels HG, Liu Y, **Hess LM**, and Alberts DS. Limits of detection of chemopreventive efficacy: karyometry of skin biopsies. Cancer Epi Biom Prev, 17(7):1689-95, 2008.

Garcia F, Bartels PH, Trimble C, Curtin J, **Hess LM**, Yozwiak M, Bartels HG and Alberts DS. Karyometric assessment of endometrial nuclei from patients with a community diagnosis of atypical endometrial hyperplasia (AEH). I - Discrimination of endometrial lesions. Under review, IJGC 2009.

Bartels PH, Garcia F, Trimble C, Curtin J, **Hess LM**, Yozwiak M, Bartels HG and Alberts DS Karyometric assessment of endometrial nuclei from patients with a community diagnosis of atypical endometrial hyperplasia (AEH). II: Heterogeneity. Under review, IJGC, 2009.

Bartels PH, Garcia F, Trimble C, Curtin J, **Hess LM**, Yozwiak M, Bartels HG and Alberts DS Karyometric assessment of endometrial nuclei from patients with a community diagnosis of atypical endometrial hyperplasia (AEH). III: Discrimination of AEH from invasive endometrial carcinoma. Under review, IJGC, 2009.

**Hess LM**. Terminology used in medication adherence research must reflect current models of health care. Value in Health, 12(4):630, 2009.

Clouser M, **Hess LM**, Chambers SK. Biomarker targets and novel therapeutics. Cancer Treat Res. 149:85-105, 2009.

**Hess LM**, Malone DC, Skrepnek GH, Reed PG, Armstrong E, Coons SJ. Oncologist preferences for health states associated with the treatment of advanced ovarian cancer. Applied Health Economics and Health Policy, accepted, 2009.

**Hess, LM**, Chambers SK, Hallum A, Janicek M, Buscema J, Slayton, L, Chongpison, Y, Calley, C, Alberts DS. Pilot Study of the Identification of Changes in Cognitive Function in Ovarian Cancer Patients. Submitted, J Supp Oncol, 2009.

**Hess LM**, Malone DC, Reed PG, Skrepnek GH, Weihs KJ. Preferences of patients and oncologists for advanced ovarian cancer treatment-related health states. Submitted, Health Outcomes Research, 2009.

## **R E P O R T S**

**Contributor/Member:** Cancer Center Directors' Working Group, Prevention Subcommittee. Recommendations From the NCI-Designated Cancer Center Directors: Accelerating Successes Against Cancer, NIH Publication number T081. Available at: [http://cancercenters.cancer.gov/documents/Accelerating\\_Successes\\_Against\\_Cancer\\_Report.pdf](http://cancercenters.cancer.gov/documents/Accelerating_Successes_Against_Cancer_Report.pdf)

**Contributor:** The Arizona Comprehensive Cancer Control Plan. Arizona Department of Health Services. Available at: <http://www.azcancercontrol.gov/pdf/cancercontrolplan.pdf>

## **B O O K S / C H A P T E R S**

Alberts DS, Walker J, Rodriguez G, Garcia FAR, Mutter GL, Plaxe S, Carlson J, Hensley M, Trimble C, **Hess LM**, Method MM, Greene MH, and Barakat R. Prevention of Gynecological Cancers. In DiSaia, P. (ed). The Gynecologic Oncology Group: Report of 35 Years of Excellence in Clinical Research. GOG:Philadelphia, 2006.

Alberts DS, **Hess LM**, Von Hoff DD, Dorr RT. Pharmacology and Therapeutics in Gynecologic Cancer. In Hoskins, Perez, Young, Barakat, Markman, Randall (Eds). Principles and Practice of Gynecologic Oncology, 4<sup>th</sup> Ed. Lippincott, Williams and Wilkins:Philadelphia, 2008. (5<sup>th</sup> Edition)

Alberts, DS and **Hess, LM** (Editors). Fundamentals of Cancer Prevention. Second Edition. Springer-Verlag:Heidelberg, 2008.

Chambers SK and **Hess LM**. Prevention of Ovarian Cancer. In Alberts, Hess (Eds). Fundamentals of Cancer Prevention. Second Edition. Springer-Verlag:Heidelberg, 2008.

Alberts DS, Barakat RR, Daly M, Method MW, Benbrook DM, Boggess JF, Brewer MA, Brinton LA, Castle PE, Davanipour Z, Garcia FAR, Hanley MG, **Hess LM**, Hines JF, Kelaghan J, Lucci J, Minasian L, Muller C, Mutter GL, Rader JS, Rodriguez G, Sobel E and Walker JL. Prevention of Gynecologic Malignancies. In Gershenson, Gore, McGuire, Quinn, Thomas (Eds) Gynecologic Cancer: Controversies in Management. Academic Press:Philadelphia, 2004.

**Hess LM**, Chambers SK and Alberts DS. The Role of Intraperitoneal Chemotherapy. In: DeVita, Lawrence and Rosenberg (Eds). Principles and Practice of Oncology Updates, volume 22. Philadelphia:Lippincott, Williams and Wilkins. (November 2008).

**Hess LM**. Conceptual model-based research in chemotherapy-related changes in cognitive function. In: Cancer Chemotherapy-Induced Cognitive Deficits, edited by Robert B. Raffa and Ronald J. Tallarida, Landes Bioscience, 2009.

**Hess LM**. Quality of life and patient-reported outcomes. In: Alberts DS, Clouser M, **Hess LM** (Eds) Intraperitoneal Therapy for Ovarian Cancer. Springer-Verlag, forthcoming 2010.

## **P R O F E S S I O N A L M E E T I N G S : P R E S E N T A T I O N S**

**Hess LM**, Heddens DK, Earnest DL, Einspahr J, Roe D, Alberts DS. Adherence assessment in a chemoprevention clinical trial: what are we measuring? ASPO, Bethesda, MD, March 10-12, 2002.

**Hess LM**, Guillen J, Krutzsch M, Salen G, Batta A, Einspahr J, Alberts DS. A Phase I Multiple-Dose Safety and Pharmacokinetic Clinical Study of Ursodeoxycholic Acid: Results of Task II. Proc AACR, Seattle, WA, October 15-21, 2004.

**Hess LM**, Brewer MA, Coons SJ, Ranger-Moore J, Skrepnek G, Malone D and Alberts DS. Evaluation of Patient Perceptions of Care--Intraperitoneal versus Intravenous Administration of Cisplatin-based Chemotherapy Regimens for the Treatment of Ovarian Cancer. Abstract Presentation. Annual Women's Cancers Scientific Retreat. Tucson AZ, February 19, 2005.

**Hess LM**, Alberts DS, Brewer M, Chambers S, Hatch K, Borst M, Gordon A, Janicek M and Hallum H. Pilot Study of the Identification of Cognitive Dysfunction in Ovarian Cancer Patients. Oral and Abstract Presentation. Annual Women's Cancers Scientific Retreat. Tucson AZ, February 19, 2005.

**Hess LM**, Barakat R, Tian C, Ozols RF, and Alberts DS. Weight change during chemotherapy for ovarian cancer. *Journal of Clinical Oncology*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 5073.

Einspahr, JG, **Hess, LM**, Guillen, J, Green, SB, Batta, AK, Lance, P, Krutzsch, M, Lin, P, Martinez, ME, Alberts, DS. Association of baseline fecal and plasma bile acids with colorectal adenoma recurrence and high-grade dysplasia in a phase III trial of colorectal adenoma recurrence, Am Assoc for Cancer Res, Washington DC, April 1-5, 2006.

**Hess LM**, Malone, DC, Skrepnek G, Coons SJ, Weihs K. A pilot study of ovarian cancer patient preferences: empirical support for non-linear decision making processes. IPOS, London, UK, September 16-20, 2007.

Alberts DS, Martinez ME, Hakim, I, **Hess LM (presenter)**. R25 Cancer Prevention and Control Postdoctoral Fellowship Program. National Leadership Workshop on Mentoring Women in Biomedical Careers. National Institutes of Health. Bethesda, MD, November 27-28, 2007. NIH Publication No. 09-6364, p.53.

**Hess LM**, Coons SJ, Hsu C-H, Malone D, Skrepnek G, Brewer MA. A pilot study of patient preferences for cancer treatment strategies for advanced ovarian cancer. SGO, San Diego, CA, March 3-7, 2007.

**Hess LM**, Malone, DC, Skrepnek G, Armstrong E, Reed P, Weihs K. Differences in risk-taking propensity among women diagnosed with advanced ovarian cancer. APOS, Irvine, CA, February 28-March 2, 2008.

**Hess LM**, Skrepnek GH, Armstrong EP, Malone DC. Comparison of Standard Gamble Utilities and Visual Analog Scale Values in an Ovarian Cancer Patient and Oncologist Study of Cancer Treatment Preferences. ISPOR, Toronto, Canada, May 3-7, 2008.

**Hess, LM**, Chambers SK, Hallum A, Janicek M, Buscema J, Slayton, L, Chongpison, Y, Calley, C, Alberts DS. Pilot Study of the Identification of Changes in Cognitive Function in Ovarian Cancer Patients. Cancer Day, IU Simon Cancer Center, Indianapolis, IN, May 6, 2009.

## **I N V I T E D L E C T U R E S**

**2006** "Change in patient weight during platinum/paclitaxel-based chemotherapy for ovarian cancer: a Gynecologic Oncology Group study." Scientific Session, Gynecologic Oncology Group, Washington D.C., July, 2006.

**2007** "Quality of Life and Biomarker Benefits Achieved for Cervical Cancer Survivors through a Telephone Counseling Intervention." Presented on behalf of Dr. Lari Wenzel at the 9th World Congress of Psycho-Oncology, London, U.K, September, 2007.

**2008** "Understanding, Participating In, and Interpreting Research Results." Facing Our Risk of Cancer Empowered: A conference for individuals and families affected by hereditary breast and ovarian cancer. Tampa. FL, May 16-17, 2008.

**2009** "Behavioral Change Models in Public Health" Indiana Mid-America Public Health Training Center (Indiana MAPHTC). Indianapolis, IN. January 13, 2009.

## **P U B L I C S E M I N A R S**

**August 24, 2004.** "Evaluation of intraperitoneal versus intravenous administration of cisplatin-based chemotherapy regimens for the treatment of ovarian cancer." Better than Ever Public Education Forum, Tucson AZ.

**May 13, 2006.** "Social and Behavioral Science Research at the Arizona Cancer Center." Ovarian Cancer Public Education Forum, Tucson AZ.

**June 4, 2009.** "What is survivorship and what does it mean for women with ovarian cancer?" Ovar'Coming Together, Indianapolis IN.

## **T E A C H I N G**

### **ACADEMIC COURSES**

**P500/H500. "Philosophy and Principles of Health Education" Core course**, MPH program, Indiana University Purdue University Indianapolis, College of Medicine, Department of Public Health. (Course Director, Fall 2008-present)

**H650. "Educational Assessment" Readings Course**, MPH program, Indiana University Purdue University Indianapolis, College of Medicine, Department of Public Health. (Fall 2008)

---

## **ACADEMIC SEMINARS**

**December 9, 2002.** “Cost-Effectiveness of Screening Methods for the Prevention of Cervical Cancer.” Course lecture for PHSC 513, Health Technology Assessment, University of Arizona College of Pharmacy. Tucson, AZ.

**February 25, 2003.** “Erythropoietin in ovarian cancer.” Seminar lecture for PHSC 596e, Graduate Seminar in Pharmaceutical Economics, Policy, and Outcomes, University of Arizona College of Pharmacy. Tucson, AZ.

**May 6, 2003.** “Measurement of adherence in administrative databases.” Course lecture for PHSC 621, Applied Health Technology Assessment, College of Pharmacy. Tucson, AZ.

**September 8, 2003.** “Information security: your responsibilities as a student/researcher.” Seminar lecture for PHSC 596e, Graduate Seminar in Pharmaceutical Economics, Policy, and Outcomes, University of Arizona College of Pharmacy. Tucson, AZ.

**March 1, 2004.** “Cognitive changes during chemotherapy for ovarian cancer.” Seminar lecture for PHSC 596e, Graduate Seminar in Pharmaceutical Economics, Policy, and Outcomes, College of Pharmacy. Tucson, AZ.

**August 5, 2004.** “Changes in Cognitive Function during Chemotherapy.” Phoenix Gynecologic Oncologists Network Scientific Session, Scottsdale, AZ.

**September 15, 2004.** “Ursodeoxycholic Acid and Fecal Bile Acids” Seminar lecture for EPI 696B, Cancer Prevention and Control Seminar, University of Arizona College of Public Health. Tucson, AZ.

**February 19, 2005.** “Pilot Study of the Identification of Cognitive Dysfunction in Ovarian Cancer Patients” Annual Women’s Cancers Scientific Retreat, Tucson, AZ.

**June 30, 2005.** “Changes in Cognitive Function During Chemotherapy – A Pilot Study in Ovarian Cancer Patients.” Phoenix Gynecologic Oncologist Network Scientific Session, Phoenix, AZ.

**October 5, 2005.** “Conceptual Ruts: realizing we have them and how to overcome.” Seminar lecture for PHSC 596e, Graduate Seminar in Pharmaceutical Economics, Policy, and Outcomes, College of Pharmacy. Tucson, AZ.

**April 12, 2006.** “Human Papillomavirus.” Seminar lecture for PHSC 596e, Graduate Seminar in Pharmaceutical Economics, Policy, and Outcomes, College of Pharmacy. Tucson, AZ.

**April 28, 2006.** “Changes in Cognitive Function During Chemotherapy – A Pilot Study in Ovarian Cancer Patients.” Course lecture for EPI/COPH 652, Grantsmanship for a Winning Proposal, College of Public Health. Tucson, AZ.

**September 20, 2006.** “Meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer.” Seminar lecture for PHSC 596e, Graduate Seminar in Pharmaceutical Economics, Policy, and Outcomes, College of Pharmacy. Tucson, AZ.

**February 16, 2007.** Three mini-symposium talks: (1) Phase IIa study of the effect of flutamide on biomarkers in the ovaries at women of increased risk for ovarian cancer; (2) Summary of ongoing research: Longitudinal Effects of Intimate Partner Relationship Quality on Serum Oxytocin Levels in Newly Diagnosed Breast Cancer Patients and Cognitive Function study; and (3) Preliminary results of the health care preferences study. Phoenix Gynecologic Oncologist Network Data Blitz, Phoenix, AZ.

**April 11, 2007.** “Patient and Physician Health Preferences.” Seminar lecture for PHSC 596e, Graduate Seminar in Pharmaceutical Economics, Policy, and Outcomes, College of Pharmacy. Tucson, AZ.

**September 12, 2007.** “Osteoporosis prevention study: doctors, lawyers and patients, oh my!” Seminar lecture for PHSC 596e, Graduate Seminar in Pharmaceutical Economics, Policy, and Outcomes, College of Pharmacy. Tucson, AZ.

**April 28, 2008.** “Funding Resources for Postdocs.” Career Development Seminar, UA Postdoctoral Association, Arizona Health Sciences Center. Tucson, AZ.

**October 8, 2008.** “Cognitive Function Related to Treatment for Advanced Ovarian Cancer.” Cancer Control Grand Rounds, IU Simon Cancer Center, Indianapolis, IN.

**November 15, 2008.** "Outcomes Research and its Application to Gynecologic Cancer". Radiation Oncology / GYN Oncology Conference. IU Simon Cancer Center, Indianapolis, IN.

**May 13, 2009.** "Measuring health care outcomes: what is important to whom." Obstetrics and Gynecology Grand Rounds, IU School of Medicine, Indianapolis, IN.

**October 2, 2009.** "Clinical Trials: The Power and Pitfalls of Chemoprevention Research" Graduate Nutrition Program Seminar Series. Purdue University, West Lafayette, IN.

## **T E A C H I N G   G R A N T   S U P P O R T**

### **Indiana University Jump Start Program**

(Hess, P500)

This project will apply a constructivist approach to the hybrid delivery of theoretical concepts in the behavioral and social sciences as applied to individual, family and community health issues. This approach is particularly relevant in public health, which provides a professional degree (MPH) to future practitioners in community health departments, advocacy organizations, research institutions, and other public and generally not-for-private organizations.

Role: grant recipient (\$5,000)

## **R E S E A R C H   G R A N T   S U P P O R T**

### **O N G O I N G**

#### **Indiana Clinical and Translational Sciences Institute**

(Hess, PI of pilot project)

Evaluation of Maintenance Therapy as a Treatment Option for Women with Advanced Ovarian Cancer

This study will evaluate the clinical trials conducted to date using statistical methodologies to better understand the overall value of maintenance therapy as compared to observation alone.

Role: Principal Investigator (\$12,000)

#### **American Cancer Society Institutional Grant Pilot Project Program** 10/27/08- 12/31/09

(Hess, PI of pilot project fund; Swanson, PI of ACS Grant supporting the project)

Suspected Ovarian cancer and the Paths to Diagnosis: Navigating a Maze of Care

This is a mixed methods cancer control project (n=100) supported by a larger grant funded by the American Cancer Society. This study seeks to explore the process by which a patient suspected of having ovarian cancer receives an accurate diagnosis based on Anderson's Model of Total Patient Delay.

Role: Principal Investigator (\$10,300)

#### **Novartis Pharmaceuticals**

Gynecologic Oncology Group Protocol 215 (GOG-0215)

A Phase IIb Randomized Study of the Effect of Zoledronic Acid Versus Observation on Bone Mineral Density of The Lumbar Spine in Women Who Elect to Undergo Surgery That Involves Removal of Both Ovaries

This randomized clinical trial is designed to compare the effect of zoledronic acid administered every 6 months on bone loss associated with surgery (at a minimum, any surgical procedure that results in removal of both ovaries), as compared with observation alone. This is to be evaluated by measuring the change from baseline to 9 and 18 months in bone mineral density (BMD) of the lumbar spine, specifically L1-L4 dual energy X-ray absorptiometry (DEXA).

<http://ovariancancer.gog199.cancer.gov/gog215/>

Role: Co-Investigator

**Harrington Cancer Center**

Gynecologic Oncology Group Protocol (CPC-0256)

A Pilot Study of Cognitive Function during Chemotherapy for Front-Line Treatment of Advanced Ovarian Cancer

This pilot study (n=200) is designed to obtain preliminary data that to be used in the design of a future adequately powered intervention trial to prevent or reduce chemotherapy-related cognitive changes.

To design such a study, preliminary information is needed on the incidence, severity and duration of these effects. This study is designed to obtain these key data, as well as to explore possible mechanisms that may be proposed as hypotheses in a future trial.

Role: Principal Investigator (\$123,750)

**ONGOING, UNFUNDED****Decision making among treatment alternatives for abnormal uterine bleeding (AUB)**

Increasingly, patient-centered models of care are becoming the norm, whereby individuals seeking care are now responsible to be active participants of that care, and to receive treatments and services that reflect their own preferences, desires and needs. This study is designed to explore the use of web-based preference elicitation tools to further inform the decision making process in the setting of abnormal uterine bleeding (AUB).

Role: Principal Investigator

**CONCLUDED****OrthoBiotech Products LLP**

8/1/2002-7/30/2008

Pilot Study of the Identification of Cognitive Dysfunction in Ovarian Cancer Patients (Alberts/Hess-Co-PIs)

This is a prospective feasibility trial (n=30) investigating changes in cognitive function in women diagnosed with advanced epithelial ovarian cancer before and throughout primary chemotherapy.

Enrollment is near completion.

Role: Co-Principal Investigator (\$168,900)

**Chemoprevention of Skin Cancer Program Project**

7/22/92-6/30/08

NIH/NCI PO1 CA27502 (Alberts – Overall PI)

The major goals of this program project are to examine the mechanisms of skin carcinogenesis and develop effective chemoprevention strategies for melanoma and non-melanoma skin cancer. Using specialized research projects, various chemopreventive strategies are being tested in order to design and optimize laboratory-based clinical trials in patients with actinic keratoses and resected squamous and basal cell skin cancers.

Role: Core Leader/Co-Investigator (5%)

**Gynecologic Oncology Group (GOG)**

8/1/03-8/8/08

NIH/NCI U01 CA101165 (DiSaia – Overall PI)

Support for Committee Chair. The Committee Chair is responsible for the development of the scientific plans for his or her Committee and for reporting the progress of the Scientific Plans to the Grantor's president and to its members at its quarterly and semi-annual meetings.

Role: Research Administrator (74%)

**R25T Cancer Prevention and Control Postdoctoral Training Grant**

05/1/02 – 04/30/08

NIH/NCI CA CA78447 (Alberts – PI)

The Cancer Prevention and Control Postdoctoral Training Program at the Arizona Cancer Center, University of Arizona is housed in the Cancer Prevention and Control (CPC) Program. This education and training program is housed within a highly multi- and inter-disciplinary, collaborative environment in which to train postdoctoral fellows. Four to six postdoctoral fellows are trained each year, for a minimum of two years' training in cancer prevention and control.

[http://www.azcc.arizona.edu/R\\_M/fellowship1.htm](http://www.azcc.arizona.edu/R_M/fellowship1.htm)

Role: Assistant Director (20% effort)

**Better Than Ever Research Grant**

5/1/04 – 6/30/08

Evaluation of Intraperitoneal versus Intravenous Administration of Cisplatin-based Chemotherapy Regimens for the Treatment of Ovarian Cancer

This is a two-phase study: Phase I: A meta-analysis of intravenous versus intraperitoneal therapy for advanced ovarian cancer; and Phase II: A series of two pilot studies to obtain pilot data related to the health preferences for various outcomes related to ovarian cancer treatment of ovarian cancer patients and their oncologists.

Role: Principal Investigator (\$38,492)

**JOURNAL REFEREEING EXPERIENCE**

- 2005**      *Current Medical Research & Opinion*
- 2006**      *American Journal of Managed Care*
- 2007**      *Gastroenterology*  
*Expert Review of Anticancer Therapy*
- 2008**      *Journal of Clinical Epidemiology*  
*Pharmacoepidemiology and Drug Safety*  
*Value in Health*
- 2009**      *Cancer Epidemiology Biomarkers and Prevention*  
*Pharmacoepidemiology and Drug Safety*  
*Value in Health*

**ACADEMIC SERVICE ACTIVITIES**

- 2009-present**    Member, Scientific Review Committee  
Indiana University, Simon Cancer Center
- 2008-present**    Member, Quality of Life Committee  
Gynecologic Oncology Group
- 2009**            Program Committee Member  
Winter Symposium, "Issues in Gynecologic Cancer Prevention and Survivorship"  
Garden Grove, CA. January 22, 2009

**COMMUNITY SERVICE ACTIVITIES**

- 2009-present**    Ovar'Coming Together, Indianapolis IN
- 2005-present**    Compassion International, Sponsor for children in Brazil and Guyana.
- 2007-2008**      Amor, Inc. Puerto Peñasco, Mexico community development projects.
- 2004-2006**      Coordinator and facilitator, Ministry Life Groups, Pantano Church, Tucson, AZ
- 2001-2003**      Hope, Inc. Tucson, AZ
- 1998-2003**      Kingdom Kids. Elementary Children's Program Coordinator/Supervisor, Tucson, AZ
- 1994-1996**      Habitat for Humanity, Tucson, AZ and Belo Horizonte, Brazil